XERIS BIOPHARMA HOLDINGS INC
Total Alternative Signals
Weighted Sentiment
Avg Materiality Score
Signal Distribution
Alternative Data Signal Feed
Unlock Alternative Signals Feed
Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for XERIS BIOPHARMA HOLDINGS INC. Programmatic API and Webhooks available.
Signal Event Report - FIGI BBG012V1MG52
Xeris Biopharma Holdings Inc. filed a current report regarding the submission of matters to a vote of security holders, likely related to an annual meeting or other corporate governance decisions such as director elections.
This filing indicates routine corporate governance activity, likely related to board elections or other standard shareholder approvals, and does not immediately alter the long-term investment thesis without further details on the specific matters voted upon.
Signal Event Report - FIGI BBG012V1MG52
Xeris Biopharma Holdings Inc. filed a current report detailing unregistered sales of equity securities and other events, indicating a capital raise or a new strategic development.
This event suggests the company is securing capital, which can fund operations, R&D, or expansion, potentially strengthening its financial position and supporting long-term growth.
Signal Event Report - FIGI BBG012V1MG52
Xeris Biopharma received a Notice of Allowance for U.S. Patent Application No. 17/151,405, covering its Keveyis product, which is expected to provide intellectual property protection through 2039.
The anticipated issuance of this patent extends intellectual property protection for Keveyis until 2039, securing a key revenue stream and strengthening the company's competitive position, which is a positive long-term driver for XERS.
Signal Event Report - FIGI BBG012V1MG52
Xeris Biopharma received a Notice of Allowance from the USPTO for a new patent covering KEVEYIS®, strengthening its intellectual property protection for a key commercialized product. This enhances the company's competitive position and potential for future revenue from the drug.
The new patent allowance for KEVEYIS® reinforces Xeris's intellectual property portfolio, providing a stronger competitive moat and potentially extending the revenue exclusivity period for a significant product. This enhances the long-term value proposition by securing future cash flows and reducing competitive risks.